Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080367 | 0.86 | ALDH1A1 (0.32) | SMN1; SMN2 | |
| SCHEMBL16631717 | 0.86 | DDB1 (0.38) | DDB1CRBNMAOAMAOBGRIN1 | |
| SCHEMBL18080373 | 0.85 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL18080370 | 0.80 | ESRRA (0.46) | DDB1CRBNMAOA | |
| SCHEMBL18080377 | 0.79 | CYP19A1 (0.48) | MAOAMAOB | |
| SCHEMBL16631713 | 0.78 | HTT (0.32) | — | |
| SCHEMBL18080360 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL18080399 | 0.75 | KCNMA1 (0.54) | — | |
| SCHEMBL18080393 | 0.75 | CYP19A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL18080371 | 0.75 | MAOA (0.34) | DDB1CRBNMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | DDB1 620/4885CRBN 2319/4885MAOA 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.